Medivation pushes Xtandi to out-do J&J’s Zytiga in prostate cancer
This article was originally published in Scrip
Executive Summary
Medivation says it sees the best commercial opportunity with its new prostate cancer drug Xtandi (enzalutamide) in the "pre-chemo label", which is currently being studied in the Phase III PREVAIL study. This may allow the company to work around an apparent obstruction to the drug's progress, the prior presence on the market of J&J's Zytiga (abiraterone).